Sepanyol - Sepanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan ire healthcare limited - trandolapril - cÁpsula dura - 2 mg - trandolapril 2 mg - trandolapril

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

glaxo group ltd. - amprenavir - infecciones por vih - antivirales para uso sistémico - agenerase, en combinación con otros agentes antirretrovirales, está indicado para el tratamiento de inhibidores de la proteasa (ip) adultos con infección por vih-1 y niños mayores de 4 años con experiencia. las cápsulas de agenerase normalmente deben administrarse con dosis bajas de ritonavir como potenciador farmacocinético de amprenavir (ver secciones 4. 2 y 4. la elección de amprenavir debe basarse en las pruebas de resistencia viral individual y en el historial de tratamiento de los pacientes (ver sección 5. el beneficio de agenerase potenciado con ritonavir no ha sido demostrada en pi nave pacientes (ver sección 5.

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptina, metformin hidrocloruro - diabetes mellitus, tipo 2 - drogas usadas en diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

novartis europharm limited - vildagliptina, metformin hidrocloruro - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Sepanyol - Sepanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

krka d.d. novo mesto - vildagliptina - comprimido - 50 mg - vildagliptina 50 mg - vildagliptina

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - avandamet está indicado en el tratamiento de la diabetes mellitus tipo 2 pacientes, particularmente en pacientes con sobrepeso:que son incapaces de alcanzar la suficiente control glucémico en su dosis máxima tolerada de oral de metformina sola. en triple terapia oral con sulfonilureas en pacientes con insuficiente control de la glucemia a pesar de la doble terapia oral con su dosis máxima tolerada de metformina y una sulfonilurea (véase la sección 4.

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

novartis europharm limited - vildagliptina - diabetes mellitus, tipo 2 - drogas usadas en diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 y 5. 1 para datos disponibles sobre diferentes combinaciones).

Sepanyol - Sepanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

lab. angenerico, s.l. - lisinopril dihidrato - excipientes: croscarmelosa sodica,manitol (e-421),almidon de maiz - inhibidores de la eca, monofÁrmacos - inhibidores de la eca, monofármacos - lisinopril

Sepanyol - Sepanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

lab. angenerico, s.l. - lisinopril dihidrato - excipientes: manitol (e-421),croscarmelosa sodica,almidon de maiz - inhibidores de la eca, monofÁrmacos - inhibidores de la eca, monofármacos - lisinopril

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamida - neoplasmas prostáticos - terapia endocrina - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.